http://rdf.disgenet.org/resource/nanopub/NP741264.RA_cFxf3jK-_2_0NubJqpJZ9vJEmf22EdQYrLo3sqXfdU
type: Nanopublication
created: 2016-05-13T12:47:21+02:00
rights: http://opendatacommons.org/licenses/odbl/1.0/
rights holder: IBIGroup
subject: SIO_000983
used data: disgenetv3.0rdf
authored by: http://orcid.org/0000-0001-5999-6269
authored by: http://orcid.org/0000-0002-7534-7661
authored by: 0000-0002-9383-528X
authored by: http://orcid.org/0000-0003-0169-8159
authored by: http://orcid.org/0000-0003-1244-7654
created by: http://orcid.org/0000-0003-0169-8159
version: v4.0.0.0

http://rdf.disgenet.org/resource/nanopub/NP741264.RA_cFxf3jK-_2_0NubJqpJZ9vJEmf22EdQYrLo3sqXfdU130_assertion
type: Assertion
description: [The 2001 World Health Organization (WHO) classification of myeloid malignancies included these MPDs under the broader category of chronic myeloproliferative diseases (CMPD), which also included chronic neutrophilic leukemia, chronic eosinophilic leukemia/hypereosinophilic syndrome (CEL/HES), and CMPD, unclassifiable. The revised 2008 WHO classification system featured the following changes: 1) the term CMPD was replaced by myeloproliferative neoplasm (MPN), 2) mast cell disease was formally included under the category of MPN, and 3) the subcategory of CEL/HES was reorganized into CEL not otherwise specified (CEL-NOS) and myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1; CEL-NOS remained a subcategory of MPN, whereas the latter neoplasms were now assigned a new category of their own.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine.
evidence: DisGeNET evidence - LITERATURE
SIO_000772: http://identifiers.org/pubmed/19472396
was generated by: ECO_0000203

befree-2016
imported on: 2016-02-19

DisGeNET evidence - LITERATURE
type: ECO_0000212
comment: Gene-disease associations inferred from text-mining the literature.

disgenetv3.0rdf
version: v4.0.0